# Shaanxi Micot Presents MT200605 Clinical Data for Stroke and Huntington's Disease

- URL: https://stocks.freetheai.org/news/shaanxi-micot-presents-mt200605-clinical-data-for-stroke-and-huntington-s-8a58e2
- Published: 2026-10-12T08:52:53Z
- Category: company_news; sentiment: bullish; impact: medium
- Symbols: [HKEX:2335](https://stocks.freetheai.org/symbols/HKEX-2335)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

Shaanxi Micot Pharmaceutical Technology Co., Ltd. (HKEX:2335) presented early-stage clinical and preclinical trial results for its drug candidate MT200605 at the MDS 2026 conference. The drug demonstrated mild adverse events and predictable safety characteristics in Phase I trials involving healthy volunteers, alongside nonclinical Huntington's disease mouse data showing improved motor function and reduced tissue atrophy.

The presentations complement earlier Phase II findings in patients with acute ischemic stroke, where high doses of MT200605 produced statistically significant functional benefits. The stroke study also revealed an exploratory finding of more than 80 percent lower incidence of acute kidney injury compared to placebo, suggesting potential application across both neurological and renal conditions. Shares of Shaanxi Micot fell 0.82 percent to 21.9 HKD following the update.

Moving forward, key milestones for the company will include advancing MT200605 into larger Phase III trials for acute ischemic stroke and progressing patient studies for Huntington's disease to confirm these therapeutic benefits.

## Key points

- Phase I testing of MT200605 in healthy volunteers showed mild adverse events and predictable pharmacokinetics.
- Preclinical mouse studies for Huntington's disease demonstrated improvements in motor skills and reduced brain atrophy.
- Prior Phase II acute ischemic stroke trials showed significant functional benefits at high doses and over 80 percent lower acute kidney injury incidence versus placebo.
- Shaanxi Micot Pharmaceutical Technology Co., Ltd. Class H shares dipped 0.82 percent to 21.9 HKD.

## Questions and answers

### What trial data did Shaanxi Micot present for MT200605?

Shaanxi Micot presented Huntington's disease mouse data and Phase I healthy volunteer safety results for MT200605, while referencing positive Phase II results in acute ischemic stroke.

### What were the key findings in Shaanxi Micot's stroke trial?

High doses of MT200605 provided significant functional benefits in acute ischemic stroke patients and showed an exploratory rate of acute kidney injury more than 80 percent lower than placebo.

### How did Shaanxi Micot stock react to the news?

Shares of Shaanxi Micot Pharmaceutical Technology Co., Ltd. Class H fell 0.82 percent to 21.9 HKD.